Regulators at the U.S. Food and Drug Administration declined to approve a needle-free nasal spray equivalent to an EpiPen, pending further study, according to the company developing it. ARS Pharma developed the product, Neffy, which is inhaled and would have been available by prescription if approved. Neffy would be a first-of-its-kind alternative to an EpiPen, which is commonly used to treat anaphylaxis, or severe allegoric reactions. The company will have an opportunity to run additional studies and apply for approval again. FDA declines to approve nasal spray alternative to EpiPen, seeking further study, company says originally appeared on abcnews.go.com

Source: ABC News September 20, 2023 18:40 UTC